Amerikanische Gesellschaft für Hirudotherapie

Activity-Dependent Modulation of Tonic GABA Currents by Endocannabinoids in Hirudo verbana

Basic science published in Front Synaptic Neurosci (2022)

Zuletzt aktualisiert: June 18, 2026Geprüft von: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Research reportGenomik & ProteomikSpeichel-PharmakologiePaulsen RT, Burrell BD · Frontiers in synaptic neuroscience, 2022

Abstract

Endocannabinoids are lipid neuromodulators that are synthesized on demand and primarily signal in a retrograde manner to elicit depression of excitatory and inhibitory synapses. Despite the considerable interest in their potential analgesic effects, there is evidence that endocannabinoids can have both pro-nociceptive and anti-nociceptive effects. The mechanisms contributing to the opposing effects of endocannabinoids in nociception need to be better understood before cannabinoid-based therapies can be effectively utilized to treat pain. Using the medicinal leech, Hirudo verbana, this work investigates whether endocannabinoids modulate tonic inhibition onto non-nociceptive afferents. In voltage clamp recordings, we analyzed changes in the tonic inhibition in pressure-sensitive (P) cells following pre-treatment with endocannabinoids, 2-arachidonoylglycerol (2-AG) or anandamide (AEA). We also tested whether high frequency stimulation (HFS) of nociceptive (N) cells could also modulate tonic inhibition. Both endocannabinoid application and N cell HFS depressed tonic inhibition in the P cell. Depression of tonic inhibition by N cell HFS was blocked by SB 366791 (a TRPV1 inhibitor). SB 366791 also prevented 2-AG-and AEA-induced depression of tonic inhibition. HFS-induced depression was not blocked by tetrahydrolipstatin (THL), which prevents 2-AG synthesis, nor AM 251 (a CB1 receptor inverse agonist). These results illustrate a novel activity-dependent modulation of tonic GABA currents that is mediated by endocannabinoid signaling and is likely to play an important role in sensitization of non-nociceptive afferent pathways.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal Article

Zusammenfassung

Endocannabinoids 2-AG and anandamide depress tonic GABA inhibition in Hirudo verbana pressure-sensitive cells via TRPV1, providing a model for nociceptive sensitization mediated by endocannabinoids.

Warum dies für die Hirudotherapie relevant ist

This study used the medicinal leech Hirudo verbana to investigate whether endocannabinoids modulate tonic GABA inhibition onto non-nociceptive afferents, finding that both exogenously applied endocannabinoids (2-AG and AEA) and high-frequency stimulation of nociceptive neurons depressed tonic inhibition in pressure-sensitive cells. The depression was blocked by the TRPV1 inhibitor SB 366791 but not by 2-AG synthesis inhibitors or CB1 receptor inverse agonists, suggesting a novel activity-dependent endocannabinoid modulation pathway relevant to sensitization of non-nociceptive afferents. This work is relevant to ASH's domain as it leverages the medicinal leech nervous system as a model to study neuromodulatory mechanisms of nociception. The study is purely basic neuroscience with no investigation of therapeutic applications, the leech secretome, or hirudotherapy.

Zitation

Activity-Dependent Modulation of Tonic GABA Currents by Endocannabinoids in Hirudo verbana.

Paulsen RT, Burrell BD · Frontiers in synaptic neuroscience, 2022

Verwandter klinischer Kontext

Zur ASH-Bibliothek hinzugefügt: May 27, 2026 · Letzte Aktualisierung der Website: June 18, 2026

Diese Website stellt Bildungsinformationen bereit und ist weder eine medizinische Beratung noch eine Diagnose oder Behandlungsempfehlung. Die medizinische Blutegeltherapie ist mit klinisch relevanten Risiken verbunden und sollte ausschließlich von qualifizierten Klinikerinnen und Klinikern unter institutionell genehmigten Protokollen durchgeführt werden. Die FDA-510(k)-Zulassung für medizinische Blutegel ist auf bestimmte Indikationen beschränkt; experimentelle und Off-Label-Diskussionen werden entsprechend gekennzeichnet. Für patientenspezifische Beratung wenden Sie sich an eine qualifizierte Gesundheitsfachkraft.